Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521572 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16690101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2521573 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16081101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2512431 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19821287 | 0.95 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| US-20240226131-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118234499-A | 2 '-Chloro-2' -fluoro-N for use in flavivirus therapy2-Amino-N6Methylaminopurine nucleotides | 阿堤亚制药公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-3831388-B1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS | FUJIFILM CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023034617-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-2909222-B1 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-2852603-B1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10717758-B2 | D-amino acid compounds for liver disease | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10618926-B2 | Process for making phosphoramidate protected nucleoside compounds | MERCK SHARP & DOHME (US) | 2020-04-14 | — | — | US | disclosed |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | UNIVERSITE DE MONTPELLIER (FR) | 2016-01-07 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
| US-20140364446-A1 | 1',4'-THIO NUCLEOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2014-12-11 | — | — | US | disclosed |
| US-20140140951-A1 | D-Alanine Ester of Rp-Nucleoside Analog | IDENIX PHARMACEUTICALS LLC | 2014-05-22 | — | — | US | disclosed |
| WO-2014066239-A1 | 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013177219-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | IDENIX PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226131-A1 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | NSUN2, PNP, METTL3 | BTN3A1 3663/4885CYP3A4 3095/4885CYP2C9 3532/4885 |
| US-10717758-B2 | D-amino acid compounds for liver disease | AADAT, BCAT1, BCAT2 | BTN3A1 2388/4885CYP3A4 3762/4885CYP2C9 3241/4885 |
| US-10618926-B2 | Process for making phosphoramidate protected nucleoside compounds | PNP, NUDT1, RNGTT | BTN3A1 2834/4885CYP3A4 1804/4885CYP2C9 402/4885 |
| US-20140140951-A1 | D-Alanine Ester of Rp-Nucleoside Analog | PNP, ANPEP, GOT1 | BTN3A1 4552/4885CYP3A4 2217/4885CYP2C9 1830/4885 |
| US-20140364446-A1 | 1',4'-THIO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, TPMT | BTN3A1 1981/4885CYP3A4 613/4885CYP2C9 696/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885CYP3A4 817/4885CYP2C9 620/4885 |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | AADAT, BCAT1, BCAT2 | BTN3A1 2388/4885CYP3A4 3762/4885CYP2C9 3241/4885 |
| US-10723754-B2 | 2′,4′-bridged nucleosides for HCV infection | SLC29A1, SLC28A1, SLC29A2 | BTN3A1 2072/4885CYP3A4 798/4885CYP2C9 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.